
AstraZeneca Plc will acquire U.S. based Alexion Pharmaceuticals in a $39 billion deal, the company said in a statement on Saturday.
Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares per Alexion share, the company said.